Join Growin Stock Community!

Arcus biosciences, inc.RCUS.US Overview

US StockHealthcare
(No presentation for RCUS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

RCUS AI Insights

RCUS Overall Performance

RCUS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

RCUS Recent Performance

10.21%

Arcus biosciences, inc.

0.05%

Avg of Sector

-0.31%

S&P500

RCUS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

RCUS Key Information

RCUS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

RCUS Profile

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

Price of RCUS

RCUS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

RCUS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.51
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
10.20
PB Ratio
5.55
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-142.91%
Revenue Growth (YoY)
-4.26%
Profit Growth (YoY)
-4.26%
3-Year Revenue Growth
-0.65%
3-Year Profit Growth
-0.65%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.51
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
10.20
PB Ratio
5.55
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-142.91%
Revenue Growth (YoY)
-4.26%
Profit Growth (YoY)
-4.26%
3-Year Revenue Growth
-0.65%
3-Year Profit Growth
-0.65%

  • When is RCUS's latest earnings report released?

    The most recent financial report for Arcus biosciences, inc. (RCUS) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating RCUS's short-term business performance and financial health. For the latest updates on RCUS's earnings releases, visit this page regularly.

  • What is the operating profit of RCUS?

    According to the latest financial report, Arcus biosciences, inc. (RCUS) reported an Operating Profit of -114M with an Operating Margin of -345.45% this period, representing a decline of 10.68% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is RCUS's revenue growth?

    In the latest financial report, Arcus biosciences, inc. (RCUS) announced revenue of 33M, with a Year-Over-Year growth rate of 26.92%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does RCUS have?

    At the end of the period, Arcus biosciences, inc. (RCUS) held Total Cash and Cash Equivalents of 222M, accounting for 0.19 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does RCUS go with three margins increasing?

    In the latest report, Arcus biosciences, inc. (RCUS) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -345.45%%, and net margin of -321.2%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess RCUS's profit trajectory and future growth potential.

  • Is RCUS's EPS continuing to grow?

    According to the past four quarterly reports, Arcus biosciences, inc. (RCUS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.9. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of RCUS?

    Arcus biosciences, inc. (RCUS)'s Free Cash Flow (FCF) for the period is -121M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 19.8% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of RCUS?

    The latest valuation data shows Arcus biosciences, inc. (RCUS) has a Price-To-Earnings (PE) ratio of -7.2 and a Price/Earnings-To-Growth (PEG) ratio of 0.24. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.